Compare ARK Genomic Revolution ETF (ARKG) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Virgin Galactic Holdings, Inc. — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Virgin Galactic Holdings, Inc. trades at $2.58 (market cap $330.34M). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| ARKG | SPCE | |
|---|---|---|
Sector | Sector/Thematic | Industrials |
52-Week High | $43.57 | $7.52 |
52-Week Low | $23.09 | $2.17 |
Market Cap | — | $330.34M |
Enterprise Value | — | $430.19M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Virgin Galactic (SPCE) trades at $2.57, down 1.91% on the day, with a bearish technical signal from moving averages. The company continues to report significant losses with negative gross profit margins of -6,127.71% and net income margin of -19,781.3% for 2025. Recent news highlights volatility in space stocks following SpaceX's IPO, with SPCE experiencing sharp price swings. Cash flow remains negative at -$35.17 million for 2025, though showing improvement from previous years.
The outlook remains challenging with persistent operational losses and high cash burn. Investment opportunity exists if the company can achieve commercial scale and profitability, but risks include execution challenges, competitive pressure, and dependence on additional financing. Analyst consensus is divided with 29% buy, 41% hold, and 29% sell ratings, reflecting uncertainty about the company's path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
